Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Union Therapeutics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Niclosamide

            Therapeutic Area: Infections and Infectious Diseases Product Name: UNI91103

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 21, 2020

            Details:

            Niclosamide based nasal spray (UNI91103) will first be investigated in high risk patients to test its ability to prevent infection with COVID-19 and to reduce the severity of the disease for those already infected.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Niclosamide

            Therapeutic Area: Infections and Infectious Diseases Product Name: UNI911

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 25, 2020

            Details:

            UNION has successfully completed inhalation dosing of 44 healthy volunteers, confirming the safety and tolerability of UNI911. UNI911 utilizes an optimized salt form of niclosamide, an existing potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Niclosamide

            Therapeutic Area: Infections and Infectious Diseases Product Name: UNI911

            Highest Development Status: IND Enabling Product Type: Small molecule

            Recipient: TFF Pharmaceuticals

            Deal Size: $210.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 13, 2020

            Details:

            UNION therapeutics completed an agreement with TFF Pharmaceuticals to acquire an option to obtain a worldwide exclusive license for the use of their Thin Film Freezing technology in combination with niclosamide to focus on treatments for COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Niclosamide

            Therapeutic Area: Infections and Infectious Diseases Product Name: UNI911

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 01, 2020

            Details:

            Danish Medicines Agency has approved initiation of a clinical study with an optimized salt form of niclosamide as a new treatment candidate for COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Niclosamide

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Institut Pasteur Korea

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 12, 2020

            Details:

            UNION therapeutics launch of a program to test an optimized salt form of niclosamide as a treatment of COVID-19, in collaboration with Institut Pasteur Korea.